OLD Republic International Corp Sells 10,250 Shares of Bristol-Myers Squibb (NYSE:BMY)

OLD Republic International Corp decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 608,750 shares of the biopharmaceutical company’s stock after selling 10,250 shares during the quarter. OLD Republic International Corp’s holdings in Bristol-Myers Squibb were worth $31,235,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BMY. Addison Advisors LLC grew its stake in Bristol-Myers Squibb by 6.6% during the third quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 192 shares during the last quarter. Symphony Financial Ltd. Co. increased its holdings in Bristol-Myers Squibb by 4.1% during the 3rd quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 194 shares in the last quarter. Blue Bell Private Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares in the last quarter. AMG National Trust Bank grew its holdings in shares of Bristol-Myers Squibb by 1.0% during the third quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company’s stock worth $1,143,000 after purchasing an additional 201 shares during the last quarter. Finally, Westside Investment Management Inc. increased its stake in shares of Bristol-Myers Squibb by 2.9% in the fourth quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock valued at $367,000 after buying an additional 204 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Trading Down 0.1 %

Shares of BMY traded down $0.05 during trading hours on Friday, reaching $44.69. The stock had a trading volume of 2,737,747 shares, compared to its average volume of 15,542,346. The firm has a 50-day moving average of $49.84 and a 200 day moving average of $50.39. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The company has a market cap of $90.59 billion, a P/E ratio of -14.45, a P/E/G ratio of 14.82 and a beta of 0.45. Bristol-Myers Squibb has a 52 week low of $43.33 and a 52 week high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. During the same quarter last year, the firm posted $2.05 earnings per share. Bristol-Myers Squibb’s revenue was up 4.7% compared to the same quarter last year. On average, sell-side analysts expect that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were issued a dividend of $0.60 per share. The ex-dividend date was Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.37%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BMY shares. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Wells Fargo & Company increased their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. BMO Capital Markets lowered their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.